A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS

Paused · Phase 1

Conditions studied: MDS

In brief

This is an open-label, phase 1b study to evaluate the safety, tolerability and preliminary efficacy of IBI188 in combination with Azacitidine in newly diagnosed higher risk MDS patients.

Key facts

Study ID

NCT04511975

Run by

Innovent Biologics (Suzhou) Co. Ltd.

People needed

32

Starts

2020-08-24

Expected to finish

2022-04-04

Last updated by the study team

2020-12-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• American Oncology Partners of Maryland, PA — Bethesda, Maryland, United States
• New Jersey Center for Cancer Research — Brick, New Jersey, United States
• Gabrail Cancer Center — Canton, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.